Award

ALMAC - active and placebo capsule manufacture for the LAMDARCT Clinical Trial

BELFAST HEALTH & SOCIAL CARE TRUST

This public procurement record has 3 releases in its history.

TenderCancellation

08 Dec 2025 at 15:19

UK12 - Procurement Termination Notice
Award

11 Aug 2025 at 15:30

UK6 - Contract Award Notice
Award

11 Aug 2025 at 15:13

UK5 - Transparency Notice
Summary of the contracting process

The Belfast Health & Social Care Trust initiated a procurement process for the manufacture of active and placebo capsules for the LAMDARCT Clinical Trial, under the legal framework of the UK Public General Acts 2023. The title of this procurement is "ALMAC - active and placebo capsule manufacture for the LAMDARCT Clinical Trial", and its main procurement category is goods within the pharmaceutical industry, located in the United Kingdom. Originally, the procurement was set as a direct award to ALMAC Clinical Services Limited, with a contract period from 1st November 2025 to 1st November 2029. Due to changes in start dates, value, and scope, the initial contract was cancelled on 8th December 2025, and new notices (UK5 and UK6) are to be published for the revised tender.

This procurement represents significant business growth opportunities by catering to the niche market of clinical trial supplies, especially the pharmaceutical segment focusing on innovative and cost-effective treatments for conditions such as age-related macular degeneration. Large pharmaceutical manufacturers with expertise in producing clinical trial materials and possessing the necessary MHRA licensing would be well-suited to compete. Being adept in delivering complex pharmaceutical products on a larger scale will also be a competitive advantage for suppliers interested in participating in the revised procurement process.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Start Free Trial Book a Demo
All Features Pricing

Notice Information

Notice Title

ALMAC - active and placebo capsule manufacture for the LAMDARCT Clinical Trial

Notice Description

This procurement if for active and placebo capsule manufacture for the LAMDARCT Clinical Trial .

Procurement Information

Schedule 5, (2) The public contract concerns the production of a prototype, or supply of other novel goods or services, for the purpose of (c) other research, experiment, study or development. Age-related macular degeneration (AMD) is a leading cause of visual loss. There are two main forms of AMD: dry and wet. The current wet AMD treatment is intravitreal antiVEGF injections, repeated every 4-12 weeks. Due to the cost of the medication, the route and frequency of administration, this treatment is a significant burden on the NHS budget.An additional treatment option for wet AMD is L-dopa. L-dopa is a widely available drug (used in treatment of Parkinson's), typically in the form of Carbidopa-L-Dopa. It is taken as an oral tablet and is significantly cheaper than the antiVEGF injections. The study will be a placebo-controlled clinical trial. Eligible patients will be randomised to receive either 100mg L-DOPA+25mg carbidopa or placebo twice a day, for 24 months, in addition to the current standard of care to determine if this is a more cost-effective and easier-to-administer treatment regime than the current standard of care. To 'blind' this clinical trial (to reduce bias) requires the development and manufacture of over encapsulated 100mg L-DOPA+25mg carbidopa tablets and development and manufacture of matching placebo capsules. The expertise required to develop and manufacture these capsules in the quantity required for this trial requires outsourcing to a manufacturer licensed by the MHRA possessing the necessary technical expertise.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-058571
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/080707-2025
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
UK6 - Contract Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Direct
Procurement Method Details
Direct award
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
£416,789 £100K-£500K
Contracts Value
Not specified

Notice Dates

Publication Date
8 Dec 20252 months ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
10 Aug 20256 months ago
Contract Period
1 Nov 2025 - 1 Nov 2029 4-5 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Active
Contracts Status
Cancelled

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
BELFAST HEALTH & SOCIAL CARE TRUST
Additional Buyers

MISSING

Contact Name
Not specified
Contact Email
financeprocurement@belfasttrust.hscni.net
Contact Phone
Not specified

Buyer Location

Locality
BELFAST
Postcode
BT12 6BA
Post Town
Northern Ireland
Country
Northern Ireland
Major Region (ITL 1)
TLN Northern Ireland
Basic Region (ITL 2)
TLN0 Northern Ireland
Small Region (ITL 3)
TLN06 Belfast
Delivery Location
Not specified
Local Authority
Belfast
Electoral Ward
Falls
Westminster Constituency
Belfast West

Supplier Information

Number of Suppliers
1
Supplier Name

ALMAC CLINICAL SERVICES

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts. 

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-058571-2025-12-08T15:19:44Z",
    "date": "2025-12-08T15:19:44Z",
    "ocid": "ocds-h6vhtk-058571",
    "initiationType": "tender",
    "parties": [
        {
            "id": "GB-PPON-PLQJ-5727-JCLR",
            "name": "Belfast Health & Social Care Trust",
            "identifier": {
                "scheme": "GB-PPON",
                "id": "PLQJ-5727-JCLR"
            },
            "address": {
                "streetAddress": "Trust Headquarters, 2nd Floor, Non Clinical Support Building, Royal Victoria Hospital",
                "locality": "Belfast",
                "postalCode": "BT12 6BA",
                "country": "GB",
                "countryName": "United Kingdom",
                "region": "UKN06"
            },
            "contactPoint": {
                "email": "FinanceProcurement@belfasttrust.hscni.net"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "classifications": [
                    {
                        "id": "publicAuthorityCentralGovernment",
                        "scheme": "UK_CA_TYPE",
                        "description": "Public authority - central government"
                    },
                    {
                        "id": "GB-NIR",
                        "scheme": "UK_CA_DEVOLVED_REGULATIONS",
                        "description": "Northern Irish devolved regulations apply"
                    }
                ]
            }
        },
        {
            "id": "GB-COH-NI041905",
            "name": "ALMAC CLINICAL SERVICES LIMITED",
            "identifier": {
                "scheme": "GB-COH",
                "id": "NI041905"
            },
            "additionalIdentifiers": [
                {
                    "scheme": "GB-PPON",
                    "id": "PRCD-2287-GMQG"
                }
            ],
            "address": {
                "streetAddress": "Almac House",
                "locality": "Craigavon",
                "postalCode": "BT63 5QD",
                "country": "GB",
                "countryName": "United Kingdom",
                "region": "UKN07"
            },
            "contactPoint": {
                "email": "csrfinotifcations@almacgroup.com"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "url": "http://ww.almacgroup.com",
                "scale": "large",
                "vcse": false,
                "publicServiceMissionOrganization": false,
                "shelteredWorkshop": false
            }
        }
    ],
    "buyer": {
        "id": "GB-PPON-PLQJ-5727-JCLR",
        "name": "Belfast Health & Social Care Trust"
    },
    "tender": {
        "id": "DAC",
        "legalBasis": {
            "id": "2023/54",
            "scheme": "UKPGA",
            "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
        },
        "title": "ALMAC - active and placebo capsule manufacture for the LAMDARCT Clinical Trial",
        "description": "This procurement if for active and placebo capsule manufacture for the LAMDARCT Clinical Trial .",
        "status": "complete",
        "procurementMethod": "direct",
        "procurementMethodDetails": "Direct award",
        "procurementMethodRationale": "Schedule 5, (2) The public contract concerns the production of a prototype, or supply of other novel goods or services, for the purpose of (c) other research, experiment, study or development. Age-related macular degeneration (AMD) is a leading cause of visual loss. There are two main forms of AMD: dry and wet. The current wet AMD treatment is intravitreal antiVEGF injections, repeated every 4-12 weeks. Due to the cost of the medication, the route and frequency of administration, this treatment is a significant burden on the NHS budget.An additional treatment option for wet AMD is L-dopa. L-dopa is a widely available drug (used in treatment of Parkinson's), typically in the form of Carbidopa-L-Dopa. It is taken as an oral tablet and is significantly cheaper than the antiVEGF injections. The study will be a placebo-controlled clinical trial. Eligible patients will be randomised to receive either 100mg L-DOPA+25mg carbidopa or placebo twice a day, for 24 months, in addition to the current standard of care to determine if this is a more cost-effective and easier-to-administer treatment regime than the current standard of care. To 'blind' this clinical trial (to reduce bias) requires the development and manufacture of over encapsulated 100mg L-DOPA+25mg carbidopa tablets and development and manufacture of matching placebo capsules. The expertise required to develop and manufacture these capsules in the quantity required for this trial requires outsourcing to a manufacturer licensed by the MHRA possessing the necessary technical expertise.",
        "lots": [
            {
                "id": "1",
                "status": "complete"
            }
        ],
        "documents": [
            {
                "id": "conflictOfInterest",
                "documentType": "conflictOfInterest",
                "description": "Not published"
            },
            {
                "id": "080707-2025",
                "documentType": "tenderCancellationNotice",
                "noticeType": "UK12",
                "description": "Procurement termination notice on Find a Tender",
                "url": "https://www.find-tender.service.gov.uk/Notice/080707-2025",
                "datePublished": "2025-12-08T15:19:44Z",
                "format": "text/html"
            }
        ],
        "procurementMethodRationaleClassifications": [
            {
                "id": "prototypesDevelopment"
            }
        ]
    },
    "awards": [
        {
            "id": "1",
            "title": "Active and placebo capsule manufacture for the LAMDARCT Clinical Trial",
            "status": "active",
            "value": {
                "amountGross": 500147.1,
                "amount": 416789.25,
                "currency": "GBP"
            },
            "mainProcurementCategory": "goods",
            "aboveThreshold": true,
            "suppliers": [
                {
                    "id": "GB-COH-NI041905",
                    "name": "ALMAC CLINICAL SERVICES LIMITED"
                }
            ],
            "items": [
                {
                    "id": "1",
                    "additionalClassifications": [
                        {
                            "scheme": "CPV",
                            "id": "33600000",
                            "description": "Pharmaceutical products"
                        }
                    ],
                    "deliveryAddresses": [
                        {
                            "region": "UKN",
                            "country": "GB",
                            "countryName": "United Kingdom"
                        },
                        {
                            "region": "UKN",
                            "country": "GB",
                            "countryName": "United Kingdom"
                        }
                    ],
                    "relatedLot": "1"
                }
            ],
            "contractPeriod": {
                "startDate": "2025-11-01T00:00:00Z",
                "endDate": "2029-11-01T23:59:59Z"
            },
            "relatedLots": [
                "1"
            ],
            "documents": [
                {
                    "id": "047749-2025",
                    "documentType": "awardNotice",
                    "noticeType": "UK5",
                    "description": "Transparency notice on Find a Tender",
                    "url": "https://www.find-tender.service.gov.uk/Notice/047749-2025",
                    "datePublished": "2025-08-11T16:13:05+01:00",
                    "format": "text/html"
                },
                {
                    "id": "047756-2025",
                    "documentType": "awardNotice",
                    "noticeType": "UK6",
                    "description": "Contract award notice on Find a Tender",
                    "url": "https://www.find-tender.service.gov.uk/Notice/047756-2025",
                    "datePublished": "2025-08-11T16:30:31+01:00",
                    "format": "text/html"
                }
            ],
            "milestones": [
                {
                    "id": "1",
                    "type": "futureSignatureDate",
                    "dueDate": "2025-10-01T23:59:59+01:00",
                    "status": "scheduled"
                }
            ],
            "date": "2025-08-11T00:00:00+01:00",
            "standstillPeriod": {
                "endDate": "2025-08-20T23:59:59+01:00"
            }
        }
    ],
    "language": "en",
    "contracts": [
        {
            "id": "1",
            "awardID": "1",
            "status": "cancelled",
            "statusDetails": "Start date, value and scope have changed, a UK5 and UK6 will be published for a new procurement.",
            "finalStatusDate": "2025-12-05T00:00:00Z"
        }
    ]
}